to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Life sciences business owners are seeing a modest rise in venture capital funds – no mean feat in this economy. But one big communications mistake will take you and your firm out of the running.
An important voice in the angel investing world, Luis Villalobos has contributed a practical new term--"valuation divergence"--that focuses on a little understood fact of angel investing: Returns on investments in a company do not increase in direct proportion to the company's market valuation. Entrepreneurs and investors alike will benefit from a better understanding of this concept.
A highly successful angel investor and entrepreneur identifies and puts to the test a valuation calculator tool. He finds that it works very well, thank you. By answering twenty-five questions, entrepreneurs and investors arrive at valuations that can reasonably be used as a practical guide to investing.
Numerous factors affect how angels value a company. Primary are the strength of the management team and the size of the opportunity, or a company's potential to scale. Accompanying this article is a valuation worksheet that entrepreneurs can use to better understand what investors look for and to identify factors that can justify higher pre-money valuations. Investors will find it useful to compare companies and determine whether valuation should be higher or lower.
This informative piece explains a well-known method that venture capitalists use to determine "post-money valuation," which is a company's valuation at the time of investment. Perhaps more important, it provides valuable insights into why the returns expected by investors are often perceived as "too high" by entrepreneurs.
Finding venture capital is a matter of securing the right fit between founder and funder, writes the author. Affinity with a investor helps, such as pursuing groups that finance the type of company that yours is, such as a minority- or female-led firm; also necessary is a plan outlining your company's financial prospects and a pitch for convincing investors that you can execute, the author notes.
VCs increasingly are leaving the industry to become entrepreneurs, yet despite their experience with funding startups, many of them are realizing just how challenging it can be to launch a successful business. The insights gained in entrepreneurship, in turn, provide them with a perspective on what it means to be on the andquot;other sideandquot; of the funding table.
The venture capital climate improved in RTP in the first quarter, but biotech companies are still competing for dollars. Several RTP companies saw venture capital investment for development of pharmaceutical products and medical technologies. Read more to learn about the venture capital climate.
Hatteras Venture Partners, a venture capital firm, will invest $20 million to $30 million in helping companies through first-in-man and preclinical studies. The firm expects to invest in 10 to 15 companies in the healthcare business.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.